Zacks Research Analysts Increase Earnings Estimates for BMRN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) – Analysts at Zacks Research increased their Q2 2026 EPS estimates for shares of BioMarin Pharmaceutical in a report released on Wednesday, March 12th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of $1.00 per share for the quarter, up from their […]
